The identification of the LINC01852/TRIM72/SRSF5/PKM2 signaling axis provides new insights into the molecular mechanisms underlying drug resistance and tumor progression, identifying new therapeutic targets for CRC. This evidence concerns the gene SRSF5 and colorectal carcinoma.